* Core Laboratories NV CLB.N CLB is expected to show a
rise in
quarterly revenue when it reports results on April 26.
* The Amstelveen Noord-holland-based company is expected to
report a 9.5% increase in revenue to $126.308 million from
$115.3 million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. The company's guidance on
February 1 2023, for the period ended March 31, was for revenue
between $125.00 million and $129.00 million.
* Refinitiv's mean analyst estimate for Core Laboratories
NV is
for earnings of 16 cents per share. The company's EPS guidance
on February 1 2023, for the period ended March 31, was between
$0.14 and $0.19
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 7
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Core
Laboratories
NV is $21.75, below its last closing price of $22.00.
The company's guidance on February 1 2023 for the period ended
March 31 was for Earnings before Interest and Taxes between
USD11.5 million and USD14.5 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 0.19 0.20 0.20 Met 2.2
Sep. 30 2022 0.15 0.15 0.18 Beat 20.3
Jun. 30 2022 0.12 0.14 0.12 Missed -12
Mar. 31 2022 0.07 0.09 0.08 Missed -11.6
Dec. 0.20 0.20 0.20 Met -0.4
31 2021
Sep. 30 2021 0.18 0.19 0.18 Missed -3.8
Jun. 30 2021 0.19 0.19 0.18 Missed -6.2
Mar. 31 2021 0.12 0.13 0.15 Beat 15
This summary was machine generated April 25 at 02:32 GMT. All
figures in US dollars unless otherwise stated